C: Peg-interferon alpha-2a & Ribavirin — Competitive Intelligence Brief

C: Peg-interferon alpha-2a & Ribavirin (C: Peg-interferon alpha-2a & Ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase Virology/Hepatology Small molecule

Target snapshot

C: Peg-interferon alpha-2a & Ribavirin (C: Peg-interferon alpha-2a & Ribavirin) — Kaohsiung Medical University Chung-Ho Memorial Hospital. Pegylated interferon alpha-2a activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
C: Peg-interferon alpha-2a & Ribavirin TARGET	C: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-IFN + RBV	Peg-IFN + RBV	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-interferon alpha 2a and ribavin	Peg-interferon alpha 2a and ribavin	Hospices Civils de Lyon	phase 3	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Pegasys /RBV	Pegasys /RBV	Beijing Kawin Technology Share-Holding Co., Ltd.	phase 3	Interferon alfa-2a (pegylated) + nucleoside analog combination	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peginterferon alfa-2a, Ribavirin, epoetin-β	Peginterferon alfa-2a, Ribavirin, epoetin-β	Germans Trias i Pujol Hospital	marketed	Antiviral combination therapy with hematopoietic agent	Interferon-α receptor; viral RNA polymerase; erythropoietin receptor
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Pegylated interferon alfa-2a + Ribavirin	Pegylated interferon alfa-2a + Ribavirin	University of California, San Francisco	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
2. National Taiwan University Hospital · 6 drugs in this class
3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
4. Hepatitis Resource Network · 1 drug in this class
5. Hospices Civils de Lyon · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Pacific Health Foundation · 1 drug in this class
8. RedHill Biopharma Limited · 1 drug in this class
9. Sherief Abd-Elsalam · 1 drug in this class
10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class